Outcomes of Kawasaki Disease
暂无分享,去创建一个
S. Çelebi | F. Uysal | E. Çil | O. Bostan | Berfin Uysal | Serif Hamitoglu
[1] K. Yoon,et al. Genetic Polymorphism of SMAD5 is Associated With Kawasaki Disease , 2014, Pediatric Cardiology.
[2] R. Fukazawa. Long-term prognosis of Kawasaki disease: increased cardiovascular risk? , 2010, Current opinion in pediatrics.
[3] A. Anarat,et al. Childhood vasculitides in Turkey: a nationwide survey , 2006, Clinical Rheumatology.
[4] Walter R Wilson,et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association , 2004, Pediatrics.
[5] R. Holman,et al. Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. , 2003, Pediatrics.
[6] R. Chang. The incidence of Kawasaki disease in the United States did not increase between 1988 and 1997. , 2003, Pediatrics.
[7] K. Durongpisitkul,et al. Immunoglobulin Failure and Retreatment in Kawasaki Disease , 2003, Pediatric Cardiology.
[8] T. Southwood,et al. Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins , 2002, The Lancet.
[9] S. Colan,et al. Aortic root dilation in Kawasaki disease. , 2001, The American journal of cardiology.
[10] 橋野 かの子. Re-treatment for immune globulin-resistant Kawasaki disease : a comparative study of additional immune globulin and steroid pulse therapy , 2001 .
[11] D. Sherry,et al. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. , 2000, Pediatrics.
[12] G. B. Aydın,et al. Rheumatic heart disease prevalence among schoolchildren in Ankara, Turkey. , 1999, The Turkish journal of pediatrics.
[13] J. Newburger,et al. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. , 1998, The Pediatric infectious disease journal.
[14] S. Shulman,et al. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. , 1997, The Journal of pediatrics.
[15] K Hashino,et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. , 1996, Circulation.
[16] K. Durongpisitkul,et al. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. , 1995, Pediatrics.
[17] M. Takano,et al. Gallium-67 myocardial imaging for the detection of myocarditis in the acute phase of Kawasaki disease (mucocutaneous lymph node syndrome): the usefulness of single photon emission computed tomography. , 1987, British heart journal.
[18] A. Lewis,et al. Regression of coronary aneurysms in patients with Kawasaki syndrome. , 1987, Circulation.
[19] J. Huhta,et al. Treatment of Kawasaki syndrome with intravenous gamma globulin. , 1987, The New England journal of medicine.
[20] J. Newburger,et al. Clinical spectrum of Kawasaki disease in infants younger than 6 months of age. , 1986, The Journal of pediatrics.
[21] H. Nakano,et al. High incidence of aortic regurgitation following Kawasaki disease. , 1985, The Journal of pediatrics.
[22] Katsuko Sato,et al. HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR KAWASAKI DISEASE , 1983, The Lancet.
[23] T. Kozuka,et al. Histopathological study on right endomyocardial biopsy of Kawasaki disease. , 1980, British heart journal.
[24] Y. Hamashima,et al. Pathology of the heart in Kawasaki disease. , 1978, Pediatrics.
[25] T. Kawasaki,et al. [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]. , 1967, Arerugi = [Allergy].